A strong start, a promising future

[1]	Xiaofei Zhang, Zhuo Ma, Eli Song, Tao Xu. Islet organoid as a promising model for diabetes. Protein&Cell, 2022, 13(4): 239-257. doi: 10.1007/s13238-021-00831-0
[2]	Mona Teng, Stanley Zhou, Changmeng Cai, Mathieu Lupien, Housheng Hansen He. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein&Cell, 2021, 12(1): 29-38. doi: 10.1007/s13238-020-00786-8
[3]	Yanni Li, Xiang Jin Kang, Jeremy Kah Sheng Pang, Boon Seng Soh, Yang Yu, Yong Fan. Human germline editing: Insights to future clinical treatment of diseases. Protein&Cell, 2019, 10(7): 470-475. doi: 10.1007/s13238-018-0594-8
[4]	Xiaojuan He, Moshi Song, Jing Qu, Yansu Guo, Heqi Cao, Ruijuan Sun, Guang-Hui Liu, Yong Shen, Major Program Expert Group. Basic and translational aging research in China: present and future. Protein&Cell, 2019, 10(7): 476-484. doi: 10.1007/s13238-019-0617-0
[5]	Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein&Cell, 2018, 9(3): 254-266. doi: 10.1007/s13238-016-0367-1
[6]	Xuejiao Liu, Christopher Cervantes, Feng Liu. Common and distinct regulation of human and mouse brown and beige adipose tissues: a promising therapeutic target for obesity. Protein&Cell, 2017, 8(6): 446-454. doi: 10.1007/s13238-017-0378-6
[7]	Xiaowen Zheng, Feng Chen, Qian Zhang, Yulan Liu, Peng You, Shan Sun, Jiuxiang Lin, Ning Chen. Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease. Protein&Cell, 2017, 8(9): 686-695. doi: 10.1007/s13238-017-0413-7
[8]	Peter Roepstorff. Mass spectrometry based proteomics, background, status and future needs. Protein&Cell, 2012, 3(9): 641-647. doi: 10.1007/s13238-012-2079-5
[9]	Ming Li. A successful international cooperation with a bumpy start. Protein&Cell, 2011, 2(9): 696-698. doi: 10.1007/s13238-011-1103-5